FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 435 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Rescued From Complete Darkness July 1, 2021 Foodie Friday: Butternut Squash Macaroni Casserole September 24, 2021 Lung Cancer Treatment Research Enters a New Era October 17, 2023 EMA Recommends Granting Marketing Authorisation for Efbemalenograstim Alfa February 12, 2024 Load more HOT NEWS FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with... FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT... Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint...
